Sasha Bogdanovich

List of Publications by Year
in descending order

26 papers	3,970 citations	279798 23 h-index	580821 25 g-index
26 all docs	26 docs citations	26 times ranked	4695 citing authors

#	Article	IF	Citations
1	Overexpression of Latent TGFÎ² Binding Protein 4 in Muscle Ameliorates Muscular Dystrophy through Myostatin and TGFÎ². PLoS Genetics, 2016, 12, e1006019.	3.5	56
2	A Mouse Model for Dominant Collagen VI Disorders. Journal of Biological Chemistry, 2014, 289, 10293-10307.	3.4	35
3	Excess SMAD signaling contributes to heart and muscle dysfunction in muscular dystrophy. Human Molecular Genetics, 2014, 23, 6722-6731.	2.9	32
4	IL-18 is not therapeutic for neovascular age-related macular degeneration. Nature Medicine, 2014, 20, 1372-1375.	30.7	37
5	Targeting latent TGFÎ² release in muscular dystrophy. Science Translational Medicine, 2014, 6, 259ra144.	12.4	41
6	DICER1/ <i>Alu</i> RNA dysmetabolism induces Caspase-8â€"mediated cell death in age-related macular degeneration. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16082-16087.	7.1	79
7	COL6A3 Protein Deficiency in Mice Leads to Muscle and Tendon Defects Similar to Human Collagen VI Congenital Muscular Dystrophy. Journal of Biological Chemistry, 2013, 288, 14320-14331.	3.4	58
8	Short-interfering RNAs Induce Retinal Degeneration via TLR3 and IRF3. Molecular Therapy, 2012, 20, 101-108.	8.2	86
9	ERK1/2 activation is a therapeutic target in age-related macular degeneration. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 13781-13786.	7.1	98
10	DICER1 Loss and Alu RNA Induce Age-Related Macular Degeneration via the NLRP3 Inflammasome and MyD88. Cell, 2012, 149, 847-859.	28.9	526
11	Targeting the Activin Type IIB Receptor to Improve Muscle Mass and Function in the mdx Mouse Model of Duchenne Muscular Dystrophy. American Journal of Pathology, 2011, 178, 1287-1297.	3.8	99
12	Loss of IL-15 receptor Î± alters the endurance, fatigability, and metabolic characteristics of mouse fast skeletal muscles. Journal of Clinical Investigation, 2011, 121, 3120-3132.	8.2	72
13	DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature, 2011, 471, 325-330.	27.8	573
14	Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 762-767.	7.1	134
15	Differential Expression of Utrophinâ€A and â€B Promoters in the Central Nervous System (CNS) of Normal and Dystrophic <i>mdx</i> Mice. Brain Pathology, 2010, 20, 323-342.	4.1	16
16	Transcriptional and functional differences in stem cell populations isolated from extraocular and limb muscles. Physiological Genomics, 2009, 37, 35-42.	2.3	25
17	Myostatin blockade improves function but not histopathology in a murine model of limbâ€girdle muscular dystrophy 2C. Muscle and Nerve, 2008, 37, 308-316.	2.2	66
18	Identification and Characterization of Layer-Specific Differences in Extraocular Muscle M-Bands. , 2007, 48, 1119.		20

#	Article	IF	Citations
19	Corneal avascularity is due to soluble VEGF receptor-1. Nature, 2006, 443, 993-997.	27.8	605
20	Myostatin propeptideâ€mediated amelioration of dystrophic pathophysiology. FASEB Journal, 2005, 19, 543-549.	0.5	219
21	Structural details of rat extraocular muscles and three-dimensional reconstruction of the rat inferior rectus muscle and muscle-pulley interface. Vision Research, 2005, 45, 1945-1955.	1.4	20
22	Layer-specific differences of gene expression in extraocular muscles identified by laser-capture microscopy. Physiological Genomics, 2004, 20, 55-65.	2.3	28
23	Heregulin ameliorates the dystrophic phenotype in mdx mice. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 13856-13860.	7.1	112
24	Therapeutics for Duchenne muscular dystrophy: current approaches and future directions. Journal of Molecular Medicine, 2004, 82, 102-115.	3.9	91
25	Expression profiling reveals metabolic and structural components of extraocular muscles. Physiological Genomics, 2002, 9, 71-84.	2.3	94
26	Functional improvement of dystrophic muscle by myostatin blockade. Nature, 2002, 420, 418-421.	27.8	748